EuroQol (EQ-5D) health utility scores for patients with migraine

被引:47
作者
Xu, Ruifeng [1 ,2 ]
Insinga, Ralph P. [2 ]
Golden, Wendy [3 ]
Hu, X. Henry [3 ]
机构
[1] Merck & Co Inc, N Wales, PA 19454 USA
[2] Merck Res Labs, Dept Hlth Econ Stat, N Wales, PA USA
[3] Merck & Co Inc, Global Human Hlth, Global Outcomes Res & Reimbursement, Whitehouse Stn, NJ USA
关键词
Migraine; Headache; EQ-5D; Health utility score; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; CHRONIC MEDICAL CONDITIONS; UNITED-STATES; INDEX SCORES; PROPHYLACTIC TREATMENT; AMERICAN MIGRAINE; DOUBLE-BLIND; POPULATION; TOPIRAMATE;
D O I
10.1007/s11136-010-9783-5
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Previous studies have reported health utilities for migraine patients as generally measured between migraine attacks, but health utility data for within a migraine attack are unavailable. We evaluated within-attack health utilities among acute migraine patients experiencing different grades of headache severity. We examined data for 330 20-65-year-old adults, in good physical health, who had 1-6 moderate/severe migraine attacks per month in the 2 months prior to the screening visit. Data were collected from a multicenter, double-blind study of a treatment for acute migraine in the United States. The EQ-5D system was used to measure generic health status at baseline and 24 h post-treatment within an acute migraine attack, and patients were also asked to rate their pain level at these time points (no, mild, moderate, or severe pain). The D1 time-trade-off scoring algorithm for the U.S. population was applied. Confidence intervals were estimated by bootstrap methods. The study population was 88% women and 78% white ethnicity, with 60% of subjects over age 40. The disutility of mild migraine pain was estimated to be 0.140 (95% CI: 0.0848, 0.1940), with a disutility for moderate migraine pain of 0.186 (95% CI: 0.1645, 0.2053) and for severe migraine pain of 0.493 (95% CI: 0.4100, 0.5654). Within-attack disutilities estimated for migraine in this study are much greater than those reported for migraine when evaluated as a chronic health condition (e.g., valuations collected at random time points). These data can be of value in adapting results from clinical trials of migraine interventions to cost-utility policy analyses.
引用
收藏
页码:601 / 608
页数:8
相关论文
共 37 条
[1]  
[Anonymous], 2004, CEPHALALGIA S1, V24, P9
[2]   On the (not so) constant proportional trade-off in TTO [J].
Attema, Arthur E. ;
Brouwer, Werner B. F. .
QUALITY OF LIFE RESEARCH, 2010, 19 (04) :489-497
[3]   A case-control study on excessive daytime sleepiness in episodic migraine [J].
Barbanti, P. ;
Fabbrini, G. ;
Aurilia, C. ;
Vanacore, N. ;
Cruccu, G. .
CEPHALALGIA, 2007, 27 (10) :1115-1119
[4]   The migraine cycle: Patient burden of migraine during and between migraine attacks [J].
Brandes, Jan Lewis .
HEADACHE, 2008, 48 (03) :430-441
[5]   Migraine frequency and health utilities: Findings from a multisite survey [J].
Brown, Jeffrey S. ;
Neumann, Peter J. ;
Papadopoulos, George ;
Ruoff, Gary ;
Diamond, Merle ;
Menzin, Joseph .
VALUE IN HEALTH, 2008, 11 (02) :315-321
[6]   The impact of migraine prevention on daily activities:: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials [J].
Dahlof, Carl ;
Loder, Elizabeth ;
Diamond, Merle ;
Rupnow, Marcia ;
Papadopoulos, George ;
Mao, Lian .
HEALTH AND QUALITY OF LIFE OUTCOMES, 2007, 5 (1)
[7]   MIGRAINE PATIENTS EXPERIENCE POORER SUBJECTIVE WELL-BEING/QUALITY OF LIFE EVEN BETWEEN ATTACKS [J].
DAHLOF, CGH ;
DIMENAS, E .
CEPHALALGIA, 1995, 15 (01) :31-36
[8]   Topiramate improves health-related quality of life when used to prevent migraine [J].
Diamond, M ;
Dahlöf, C ;
Papadopoulos, G ;
Neto, W ;
Wu, SC .
HEADACHE, 2005, 45 (08) :1023-1030
[9]   Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study [J].
Diener, H-C ;
Bussone, G. ;
Van Oene, J. C. ;
Lahaye, M. ;
Schwalen, S. ;
Goadsby, P. J. .
CEPHALALGIA, 2007, 27 (07) :814-823
[10]   Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial [J].
Diener, Hans-Christoph ;
Agosti, Reto ;
Allais, Gianni ;
Bergmans, Paul ;
Bussone, Gennaro ;
Davies, Brendan ;
Ertas, Mustafa ;
Lanteri-Minet, Michel ;
Reuter, Uwe ;
Del Rio, Margarita Sdnchez ;
Schoenen, Jean ;
Schwalen, Susanne ;
van Oene, Joop .
LANCET NEUROLOGY, 2007, 6 (12) :1054-1062